SIS3 (free base)

SIS3 free base is a potent and selective inhibitor of Smad3 phosphorylation. SIS3 free base inhibits the myofibroblast differentiation of fibroblasts by TGF-β1. SIS3 free base does not affect the phosphorylation of Smad2[1].

[1]Jinnin M, et al. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006 Feb;69(2):597-607. Epub 2005 Nov 15.Antioxidants (Basel). 2022, 11(12), 2469.|Cell Biol Int. 2022 Dec 21.|Cell Transplant. 2023 Jan-Dec;32:9636897231162526.|Cell Transplant. 2023 Jan-Dec;32:9636897231177356.|FASEB J. 2022 Dec;36(12):e22625.|J ImmunoTher Cancer. 2020 Aug;8(2):e000422. |Theranostics. 2021 May 13;11(14):7110-7125.|Acta Histochem. 2023 Feb;125(2):152010.|Am J Physiol Cell Physiol. 2022 May 18.|Am J Physiol Renal Physiol. 2023 Mar 16.|Am J Reprod Immunol. 2021 Mar;85(3):e13344.|Am J Transl Res. 2020 Feb 15;12(2):478-492.|Am J Transl Res. 2021 Sep 15;13(9):10908-10921.|Antioxidants (Basel). 2022, 11(12), 2469.|Aquaculture. 15 September 2022, 738360.|Biochem Pharmacol. 2021 Nov 18;114846.|Biochem Pharmacol. 2023 Sep 8;115796.|Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3824-3836.|Biochim Biophys Acta Mol Cell Res. 2022 May 13;1869(9):119285.|Biomed Pharmacother. 2023 Jan 11;159:114216.|Biomed Pharmacother. 2023 Jul 28;165:115225.|BMC Med. 2021 Oct 15;19(1):247.|Brain Behav Immun. 2021 Mar 15;S0889-1591(21)00115-X.|Brain Res. 2021 Nov 15;147711.|Cancer Cell Int. 2024 Mar 25;24(1):114.|Cancer Cell. 2024 Apr 8;42(4):682-700.e12.|Cell Death Differ. 2021 Mar;28(3):1001-1012.|Cell Death Discov. 2021 Oct 4;7(1):273.|Chin Med. 2022 Feb 21;17(1):25.|Clin Epigenetics. 2023 Nov 11;15(1):182.|CNS Neurosci Ther. 2022 Jul 30.|Curr Med Sci. 2024 Jun 6.|Drug Dev Res. 2023 Oct 2.|EMBO Mol Med. 2024 Mar 10.|Eur Rev Med Pharmaco. 2021; 25 (2): 787-794.|Fish Shellfish Immunol. 2020 Feb;97:455-464.|Front Biosci (Landmark Ed). 2024 Sep 24;29(9):336.|Front Cell Dev Biol. 2020 Sep 18;8:858.|Front Pharmacol. 16 December 2021.|Front Pharmacol. 2018 Jun 21;9:660. |Immunol Lett. 2019 Feb;206:33-40.|Int Immunopharmacol. 2024 Sep 18;142(Pt B):113186.|Int J Clin Exp Med. 2016;9(8):15892-15899.|Int J Mol Med. 2019 Feb;43(2):993-1002. |iScience. 2023 May 29, 106994.|J Biol Chem. 2023 Dec 28:105605.|J Cell Biochem. 2019 Oct;120(10):17872-17886. |J Cell Mol Med. 2021 Nov 9.|J Cell Mol Med. 2024 Nov;28(22):e70214.|J Cell Physiol. 2023 Jun 25.|J Cell Physiol. 2020 Jan;235(1):429-441.|J Clin Transl Hepatol. May 26, 2022.|J Dent Sci. 2023 Feb 16.|J Ethnopharmacol. 2023 Feb 13;307:116243.|J Invest Dermatol. 2019 Jan;139(1):224-234.|J Pers Med. 2022, 12(3), 385.|J Tissue Eng Regen Med. 2021 Aug 7.|J Tissue Eng Regen Med. 2022 Feb 23.|Life Sci. 2023 Mar 11;320:121540.|Med Sci Monit. 2018 Nov 18;24:8290-8297.|Mol Immunol. 2018 Nov;103:173-181. |Mol Med Rep. 2019 Aug;20(2):1605-1612.|Neural Regen Res. 2024 Jan;19(1):180-189.|NPJ Regen Med. 2020 Oct 30;5(1):19.|Nucleic Acids Res. 2023 Feb 2;gkad043.|Oncogenesis. 2021 Oct 27;10(10):72.|Parasit Vectors. 2020 Apr 3;13(1):164.|Phytother Res. 2022 Oct 10.|Redox Biol. 2023 Jun, 102709.|Research Square Preprint. 2020 Nov.|Research Square Preprint. 2021 May.|Research Square Preprint. 2023 Jun 19.|Research Square Print. September 15th, 2022.|Sci Rep. 2017 Sep 8;7(1):11006. |Sci Rep. 2022 Feb 23;12(1):3053.|Stem Cell Res. 2020 Dec;49:102099.|Wright State University. 2023 Feb 23.